Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2018 Nov 20. doi: 10.1080/17512433.2018.1549485. [Epub ahead of print]

Mometasone furoate sinus implant - a new targeted approach to treating recurrent nasal polyp disease.

Author information

1
a Feinberg School of Medicine, Department of Otolaryngology - Head and Neck Surgery , Northwestern University , Chicago , IL , USA.

Abstract

Chronic rhinosinusitis (CRS) is a broad heterogeneous inflammatory disorder of the nose and paranasal sinuses, resulting from the dysfunctional interplay between host immunity, defective epithelial barrier, and environmental factors. CRS with nasal polyps (CRSwNP) is considered a more severe clinical phenotype with greater burden of symptoms and higher relapse rate, especially with comorbid asthma or aspirin sensitivity. Available treatment options after endoscopic sinus surgery (ESS) - systemic corticosteroids or revision surgery - have significant risks and limitations. Areas covered: Bioabsorbable, steroid-eluting implants have been studied extensively for the ability to dilate and re-establish sinus patency by the localized, controlled delivery of topical corticosteroids to diseased sinonasal lining and nasal polyps. This review provides a comprehensive, up to date analysis of the literature regarding a novel, office-based, mometasone furoate (MF) sinus implant that may treat patients with recurrent CRSwNP after ESS. Expert commentary: Clinical evidence has demonstrated the safety and efficacy of steroid-eluting implant in the reduction of polyp size, symptom burden, and the need for revision sinus surgery. MF sinus implants may play an important role in the management of patients with recurrent polyposis after sinus surgery.

KEYWORDS:

SINUVA; chronic rhinosinusitis; endoscopic sinus surgery; mometasone furoate; nasal polyps; sinus implant

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center